EAM
KERX

Eagle Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Eagle Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,936,365
Closed -$19.3M – 691
2015
Q2 		$19.3M Buy
1,936,365
+555,768
+40% +$5.96M 0.11% 231
2015
Q1 		$17.6M Sell
1,380,597
-810,864
-37% -$10.4M 0.1% 246
2014
Q4 		$31M Buy
2,191,461
+142,733
+7% +$2.21M 0.18% 176
2014
Q3 		$28.2M Buy
2,048,728
+486,458
+31% +$7.45M 0.16% 182
2014
Q2 		$24M Buy
1,562,270
+214,929
+16% +$3.05M 0.13% 208
2014
Q1 		$23M Buy
+1,347,341
New +$20.3M 0.13% 227

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Eagle Asset Management's KERX Position: Q3 2015 in Review

Eagle Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2015, closing a stake of 1,936,365 shares — an estimated $19.3M sold.

Eagle Asset Management first reported a position in KERX in Q1 2014 and held it in 6 quarters. The position peaked at $31M in Q4 2014. 138 funds tracked by Wall St. Rank hold KERX as of Q3 2015.

  • Eagle Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • Eagle Asset Management sold 1,936,365 Keryx Biopharmaceuticals Inc shares in Q3 2015, an estimated $19.3M.
  • Eagle Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q1 2014 and held it in 6 quarters.
  • Eagle Asset Management's Keryx Biopharmaceuticals Inc position peaked at $31M in Q4 2014.
  • 138 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2015.

Based on Eagle Asset Management's 13F filing for Q3 2015, filed 20 Oct 2015.